Novuson, a spinout from the University of Washington’s highly regarded Applied Physics Laboratory’s Center for Industrial and Medical Ultrasound, is developing its Direct Therapeutic Ultrasound (DTU) technology platform for coagulation and hemostatic control in surgical and trauma procedures. DTU technology should enable clinicians to perform surgeries more quickly and to rapidly control bleeding associated with traumatic injuries. The company founders are Stuart B. Mitchell, PhD. and Francesco P. Curra, Ph.D. Novuson creates tools that reduce operational cost and operating time, eliminating bleeding complications and enhancing patient outcomes. These automatic devices use direct therapeutic ultrasound energy for fast and robust hemostasis, cauterization and division. The devices cauterize tissue from the inside out, creating a well-defined, controlled plane of cauterization. The company was founded in 2014 and based in Bothell, Washington.